Skip to main content
Sinocelltech Group Limited logo

Sinocelltech Group Limited — Investor Relations & Filings

Ticker · 688520 ISIN · CNE100003ZL3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2023-12-15 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688520

About Sinocelltech Group Limited

https://www.sinocelltech.com/

Sinocelltech Group Limited focuses on the research, development, and commercialization of innovative biologics, including monoclonal antibodies, recombinant proteins, and vaccine candidates. The company's product pipeline addresses therapeutic areas such as oncology, autoimmune disorders, hematology, and infectious diseases. Key offerings include recombinant human coagulation factor VIII for hemophilia A and a range of biosimilars. Sinocelltech leverages an integrated technology platform encompassing early-stage discovery through to large-scale industrial production. This infrastructure supports the development of high-quality biological medicines aimed at addressing unmet medical needs through advanced protein engineering and cell line development.

Recent filings

Filing Released Lang Actions
神州细胞未来三年（2023年-2025年）股东分红回报规划
Regulatory Filings Classification · 90% confidence The document is titled as a "Future Three-Year (2023-2025) Shareholder Dividend Return Plan" issued by the company's board of directors. It details the company's dividend policy, profit distribution principles, cash dividend conditions, decision-making procedures, and shareholder return planning for the next three years. The content focuses on dividend planning and shareholder return mechanisms rather than announcing actual dividend amounts or payments. It is a policy or planning document rather than a report of financial results or an announcement of dividend payments. The document length is about 2804 characters, which is relatively short but contains substantive policy content rather than a simple announcement or notice. It does not fit categories like Notice of Dividend Amount (DIV) which would announce specific dividend amounts and payment dates, nor is it a regulatory filing or report publication announcement. The best fitting category is "Declaration of Voting Results & Voting Rights Announcements (DVA)" is not appropriate as this is not voting results. It is also not a proxy solicitation or AGM information. The document is a formal policy statement on dividend distribution and shareholder return planning, which aligns best with a Regulatory Filing (RNS) as a general regulatory announcement and policy disclosure that does not fit other specific categories.
2023-12-15 Chinese
神州细胞关于2023年度向特定对象发行A股股票预案披露的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (497 characters) regarding the company's plan to issue A shares to specific investors in 2023. It mentions board and supervisory meetings approving the proposal and references further details on the stock exchange website. It explicitly states that this disclosure is a preliminary announcement and does not represent approval or registration completion. There are no financial statements or detailed financial data included. The document is an announcement about a capital raising plan (share issuance) rather than the actual issuance or detailed report. Therefore, it fits the category of Capital/Financing Update (CAP).
2023-12-15 Chinese
神州细胞自愿披露关于控股子公司新冠疫苗SCTV01E-2被纳入紧急使用的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by Beijing Shenzhou Cell Biotechnology Group Co., Ltd. regarding the emergency use authorization of a COVID-19 vaccine developed by its subsidiary. It contains no financial statements, no detailed financial data, no regulatory certifications, or meeting materials. It is an announcement about a product approval and its potential impact on the company, not a financial report or regulatory filing. The document length is short (1537 characters) and it is an announcement of a significant corporate event related to product approval. This fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories like earnings, management changes, or capital updates.
2023-12-01 Chinese
神州细胞自愿披露关于控股子公司药品注册申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Beijing Shenzhou Cell Biotechnology Group Co., Ltd. regarding the acceptance of a drug registration application by the National Medical Products Administration for a product developed by its subsidiary. It contains no financial statements or detailed financial data, but rather regulatory and risk disclosure information about the drug approval process and its uncertainties. The document is short (1396 characters) and serves as a formal announcement of a regulatory event related to the company's product development. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is not a certification or officer attestation. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit other specific categories.
2023-11-29 Chinese
神州细胞2023年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2023 年第三季度报告' which translates to '2023 Third Quarter Report'. It contains detailed financial data including income statement, balance sheet, cash flow statement, and notes for the third quarter of 2023. The report is unaudited as indicated. The content includes comprehensive financial figures and analysis for a period shorter than a full fiscal year (quarterly). This matches the definition of an Interim / Quarterly Report (IR). The document length is over 12,000 characters and contains substantive financial data, not just an announcement or certification. Therefore, it is classified as an Interim / Quarterly Report (IR). 9M 2023
2023-10-27 Chinese
神州细胞关于召开2023年第三季度业绩说明会的公告
Regulatory Filings Classification · 95% confidence The document is an announcement about the scheduling and details of a 2023 third quarter earnings explanation meeting (业绩说明会) for Beijing Sinocell Technology Group Co., Ltd. It provides the date, time, location, format (online text interaction), and participation instructions for investors. It references that the company's 2023 Q3 report has already been disclosed on the Shanghai Stock Exchange website. The document does not contain actual financial data or detailed financial analysis but serves to inform investors about the upcoming earnings call event. According to the classification rules, such announcements about earnings explanation meetings or earnings calls are classified as Call Transcript (CT) if they contain the transcript, or as Regulatory Filings (RNS) if they are just announcements. Since this document is an announcement of the meeting and not the transcript or the earnings release itself, it fits best under Regulatory Filings (RNS). The document length is short (1575 characters), and it is clearly an announcement rather than a report or transcript. Therefore, the appropriate classification is Regulatory Filings (RNS) with high confidence.
2023-10-27 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.